Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 700 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Two Early Studies Show Rapid Antitumour CAR-Mediated Responses, but Often of... March 20, 2024 Reunión anual de la American Society of Clinical Oncology de 2021:... June 3, 2021 Pralsetinib: Measures to Minimise Increased Risk for Tuberculosis May 25, 2023 How to Cope With Waiting Periods During Cancer: An Expert Perspective June 1, 2023 Load more HOT NEWS Dual-Function Virus Engineered to Kill Tumor Cells and Support Immune Cells Colon capsule endoscopy – reshaping bowel cancer diagnosis Zilovertamab Vedotin Is Safe and Demonstrates Activity In Heavily Pretreated Patients... EMA Recommends Granting a Marketing Authorisation for Tislelizumab
